A comparative study of posaconazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease
Tài liệu tham khảo
Schofield, 2006, The future of Chagas disease control, Trends Parasitol, 22, 583, 10.1016/j.pt.2006.09.011
Moncayo, 2009, Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy, Mem Inst Oswaldo Cruz, 104, 17, 10.1590/S0074-02762009000900005
Marin-Neto, 2007, Pathogenesis of chronic Chagas heart disease, Circulation, 115, 1109, 10.1161/CIRCULATIONAHA.106.624296
Urbina, 2009, Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches, Acta Trop
Viotti, 2006, Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial, Ann Intern Med, 144, 724, 10.7326/0003-4819-144-10-200605160-00006
Minoprio, 2001, Parasite polyclonal activators: new targets for vaccination approaches?, Int J Parasitol, 31, 588, 10.1016/S0020-7519(01)00171-0
Olivieri, 2002, Benznidazole treatment following acute Trypanosoma cruzi infection triggers CD8+ T-cell expansion and promotes resistance to reinfection, Antimicrob Agents Chemother, 46, 3790, 10.1128/AAC.46.12.3790-3796.2002
Andrade, 1991, Reversibility of cardiac fibrosis in mice chronically infected with Trypanosoma cruzi, under specific chemotherapy, Mem Inst Oswaldo Cruz, 86, 187, 10.1590/S0074-02761991000200008
Segura, 1994, Reversibility of muscle and heart lesions in chronic, Trypanosoma cruzi infected mice after late trypanomicidal treatment, Mem Inst Oswaldo Cruz, 89, 213, 10.1590/S0074-02761994000200017
Andrade, 1989, Sequential changes of the connective matrix components of the myocardium (fibronectin and laminin) and evolution of cardiac fibrosis in mice infected with Trypanosoma cruzi, Am J Trop Med Hyg, 40, 252, 10.4269/ajtmh.1989.40.252
Souza, 2000, Enzymatic markers of heart lesion in mice infected with Trypanosoma cruzi and submitted to benznidazole chemotherapy, Parasitol Res, 86, 800, 10.1007/s004360000262
Ferraz, 2007, The anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas’ disease is less dependent on gamma interferon than that of benznidazole, Antimicrob Agents Chemother, 51, 1359, 10.1128/AAC.01170-06
Bustamante, 2008, Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease, Nat Med, 14, 542, 10.1038/nm1744
Ferraz, 2009, Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection, Antimicrob Agents Chemother, 53, 174, 10.1128/AAC.00779-08
Tarleton, 2007, The challenges of Chagas disease—grim outlook or glimmer of hope, PLoS Med, 4, e332, 10.1371/journal.pmed.0040332